Grant: Operating Grant - PA: Regional Partnership Program : Manitoba
University of Manitoba
$37,372.00
Risk of Non-Melanoma Skin Cancer among individuals with Inflammatory Bowel Disease: A population-based study
FY 2009-10
Summary
As compared to the rest of the world, the burden of inflammatory bowel disease is among the highest in Canada. Non-melanoma skin cancer is the commonest cancer in Canada. People with suppression of their immune system, such as those with organ transplants have an increased risk of developing non-melanoma skin cancer. Therefore individuals with organ transplants are recommended to have their skin examined regularly for skin cancers. The immune system is also altered in individuals with inflammatory bowel disease, especially among those treated with drugs which suppress the immune system. While the immune system suppression in individuals with inflammatory bowel disease is generally less than that in those with organ transplants, inflammatory bowel disease patients may still be at risk for skin cancers. The true risk of non-melanoma skin cancer in individuals with inflammatory bowel disease remains unknown.
In this study, we will determine the risk of non-melanoma skin cancer in individuals with inflammatory bowel disease as compared to that in similar age and gender individuals in the general population. We will also determine the impact of treatment with immune system suppressing drugs in individuals with inflammatory bowel disease,on the risk of non-melanoma skins cancers.
Our results will help develop recommendations for follow-up of individuals with inflammatory bowel disease to reduce their risk of having undiagnosed non-melanoma skin cancer.
Department
Program
Operating Grant - PA: Regional Partnership Program : Manitoba
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
207383
Name
Singh Harminder
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Manitoba Health Research Council
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Public, Community & Population Health
Projecttitle
Risk of Non-Melanoma Skin Cancer among individuals with Inflammatory Bowel Disease: A population-based study
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$37,372
Cihrequipment2
$0
Programname2
Operating Grant - PA: Regional Partnership Program : Manitoba
Keyworddelim
Inflammatory Bowel Disease; Non-Melanoma Skin Cancer; Population-Based Study
Abstract
As compared to the rest of the world, the burden of inflammatory bowel disease is among the highest in Canada. Non-melanoma skin cancer is the commonest cancer in Canada. People with suppression of their immune system, such as those with organ transplants have an increased risk of developing non-melanoma skin cancer. Therefore individuals with organ transplants are recommended to have their skin examined regularly for skin cancers. The immune system is also altered in individuals with inflammatory bowel disease, especially among those treated with drugs which suppress the immune system. While the immune system suppression in individuals with inflammatory bowel disease is generally less than that in those with organ transplants, inflammatory bowel disease patients may still be at risk for skin cancers. The true risk of non-melanoma skin cancer in individuals with inflammatory bowel disease remains unknown.
In this study, we will determine the risk of non-melanoma skin cancer in individuals with inflammatory bowel disease as compared to that in similar age and gender individuals in the general population. We will also determine the impact of treatment with immune system suppressing drugs in individuals with inflammatory bowel disease,on the risk of non-melanoma skins cancers.
Our results will help develop recommendations for follow-up of individuals with inflammatory bowel disease to reduce their risk of having undiagnosed non-melanoma skin cancer.
Competitiondate
201003
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Singh, Harminder; Bernstein, Charles N; Demers, Alain
Approvedterm
2 ans 0 mois
Cihrcontribution2
SPIR~ $37,372~ $0~